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Findings from an international patient registryAlthough most hereditary angioedema (HAE) attacks appear to
occur spontaneously, they can be precipitated by emotional
stressors or physical triggers, including invasive medical or
dental procedures or other physical trauma.1,2 Short-term pro-
phylaxis (STP) is appropriate for patients anticipating situations
that might precipitate an HAE attack.1,3e6 HAE guidelines
recommend that plasma-derived C1 inhibitor (C1-INH) (10e20
U/kg of Berinert [CSL Behring, King of Prussia, Pennsylvania] or
1,000 to 2,000 U of Cinryze [ViroPharma Biologics, Inc, Lex-
ington, Massachusetts]), administered within 6 hours (within 24
hours for Cinryze) before the stressor event, be used as ﬁrst-line
treatment, if available, in situations in which STP is desired.1,5,7
The plasma-derived, pasteurized, nanoﬁltered C1-INH concen-
trate (pnfC1-INH) is approved in many countries for on-demand
treatment of HAE attacks and is also approved in the European
Union for STP. Few data are currently available regarding the use
of pnfC1-INH as STP.
The Berinert Registry (clinicaltrials.gov Identiﬁer:
NCT01108848), conducted between 2010 and 2014 at 30 US and 7
European sites, represents the largest clinical research evaluation
of pnfC1-INH use and one of few data sets to describe its use for
STP.8 The registry collected data on individuals using pnfC1-INH
regardless of reason for use, and investigators were asked to
designate infusions as acute treatment, prophylaxis, or other.
During the data analysis phase, classiﬁcation of STP as the reason
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phylaxis and that were administered more than 7 days apart
from any other prophylactic infusion. STP also included infusions
that were investigator designated as prophylaxis and that were
indicated as having been administered for a medical or dental
procedure. Details regarding the procedure or event requiring
prophylaxis were not typically recorded as part of the registry
data collection.
Because the registry was designed to gather data on pnfC1-INH
use, only HAE attacks treated with pnfC1-INH were recorded. The
frequency of attacks within the ﬁrst 3 days after STP infusion is of
primary clinical interest, although a full observation period of 7
days was evaluated based on an expected washout interval of 5
half-lives after a single pnfC1-INH dose, assuming a mean half-life
of 33 hours.9 Adverse events (AEs) were identiﬁed within 30 days
after each pnfC1-INH infusion.
Approximately 1 of 4 patients in the registry (79 of 318 [24.8%])
used pnfC1-INH at least once as STP. Registry patients who used
pnfC1-INH as STP were all white, were primarily female (74.7%),
and ranged in age from 8 to 76 years (mean [SD], 42.4 [17.56] years).
Themedian pnfC1-INH dose per STP infusionwas 14.6 IU/kg (range,
3.6e33.9 IU/kg) or 1,000 IU (range, 500e3,500 IU).
The cumulative HAE attack rates within 1 and 2 days after STP
infusion regardless of dose were low at 0.04 (95% conﬁdence
interval [CI], 0.015e0.088) and 0.06 (95% CI, 0.028e0.115) attacks
per infusion, respectively, and 0.11 (95% CI, 0.061e0.174) attacks per
infusion at 3 days. From day 3 to day 4 after infusion, the cumu-
lative attack rate had the largest numerical change (þ0.12),
increasing to 0.23 (95% CI, 0.158e0.319) attacks per infusion at 4
days. Beyond 4 days, the cumulative attack rates per infusion
increased only slightly more (postinfusion day 5: 0.28; 95% CI,
0.198e0.373; day 6: 0.32; 95% CI, 0.238e0.458; and day 7: 0.35; 95%
CI, 0.261e0.458). When used for long-term prophylaxis, plasma-
derived C1-INH is recommended to be given every 3 to 4 days;
thus, an increase in attack frequency beyond 3 days of an STP
infusion is not unexpected.
Dose-response analyses of HAE attack rates 1, 3, and 7 days after
STP infusions of pnfC1-INH are presented in Figure 1, according to
weight-based dosing (Fig 1A) and absolute pnfC1-INH dose (Fig 1B).
Despite small numbers of infusions reﬂected in some dose groups,
these analyses revealed numerical trends that suggested higher
efﬁcacy with weight-based doses of 15 IU/kg and higher and ab-
solute doses of at least 1,500 IU, although the CIs overlapped,
caused in several cases by a small number of events. These trends
were most apparent at 7 days after infusion, given the small
number of attacks recorded during the ﬁrst 3 days after infusion.
There were 6 AEs reported in 5 of 79 patients (6.3%). With the
exception of 2 events of headache, all AEs were considered not
related to pnfC1-INH.
Despite the limitation of small numbers of infusions for some
dose groups and lack of observed statistical signiﬁcance, the
registry data suggest a trend toward greater efﬁcacy with higher
doses of pnfC1-INH for STP. Larger series with more complete
data would be required to further clarify these ﬁndings,
although an apparent dose-response effect is consistent with
prior experience.10 Use of adequate STP doses to provide the
highest possible degree of attack prevention is medically
important and also may avoid the added expenses of subsequent
attack treatment.
Figure 1. Dose-response analysis of cumulative hereditary angioedema (HAE)
attack rates after plasma-derived, pasteurized, nanoﬁltered C1-inhibitor concentrate
(pnfC1-INH) short-term prophylaxis (STP) infusion according to pnfC1-INH dose by
body weight (A) and absolute dose (B). Cumulative rates were based on attacks
treated with pnfC1-INH that occurred within indicated periods after pnfC1-INH
administration for STP. Comparisons between dose groups at each time point were
not statistically signiﬁcant based on overlapping conﬁdence intervals.
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patients and the observational nature and lack of a control
group or baseline attack information in the study. Only attacks
treated with pnfC1-INH were recorded in the registry. Thus,
attacks that were treated with other HAE therapies or were mild
enough to not require any treatment were not captured for
analysis, and it is therefore possible that the numerical post-STP
attack rates presented here are an underestimation. However,
the analyses that suggest a possible dose-response phenomenon
and the lowest cumulative attack rates during the ﬁrst 3 days
after infusion were founded on uniform attack deﬁnitions for
each visit; thus, the observed patterns should not have been
affected greatly by this limitation. In addition, reasons for STP or
any other use were not solicited in a proactive, mandatory
fashion, which precluded analysis of pnfC1-INH efﬁcacy for STP
for speciﬁc types of procedures or events or timing of admin-
istration relative to the prophylaxis event. Despite these limita-
tions, data from this large, international registry suggest that
pnfC1-INH is effective and safe when used for STP in patients
with HAE. A possible dose-response phenomenon was observedwith regard to the rate of HAE attacks after infusion of pnfC1-
INH for STP.
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112:58e64.Anaphylaxis induced by ingested moldsWe present the case of a 22-year-old Spanish woman residing in reactivity with 26-kDa and 57-kDa proteins in the Alternaria
Madrid with a personal history of milk and egg allergy, which she
overcame in her childhood, and seasonal allergic rhinitis and
asthma attributable to pollen allergy. No history of b-lactam allergy
was recorded. She developed 5 mild to moderate anaphylactic
reactions with generalized urticaria and angioedema in the eyelids
together with dyspnea and wheezing, nausea, and occasional
vomiting, with all symptoms appearing shortly after eating dry
curedmeat products or blue cheeses, both of which she tolerated in
the past. Neither physical exercise nor the use of any drug preceded
any of the anaphylactic reactions. All 5 reactions were treated in the
same emergency unit with intravenous corticosteroids, histamine1-
antihistamines, and inhaled salbutamol. None of the patients
received treatment with epinephrine.
The patient currently tolerates all the ingredients listed in these
foods (pork, beef, milk, sugar, spices, pepper, garlic, ascorbic acid,
sodium nitrite, and potassium nitrite). Skin prick tests (SPTs) with
standard food allergen extracts (Alk-Abelló, Hørsholm, Denmark) to
pork, beef, milk, egg, and spices (parsley, mustard, oregano, pepper,
garlic, sesame, and paprika) were performed, with negative results.
A complete battery of test inhalant allergens1 was performed,
yielding a positive result with various pollens and fungi, whereas
the SPT results were negative for house dust mites and cat and dog
dander. Phosphate-buffered saline and histamine diphosphate (100
mg/mL; Alk-Abelló) were used as negative and positive (5  5 mm)
controls, respectively. The wheals obtained with the fungal extracts
were 13  11 mmwith Alternaria, 4  4 mmwith Aspergillus, 3  4
mmwith Cladosporium, and 10 8 mmwith Penicillium. The serum
total IgE concentration was slightly elevated (225 kU/L), consistent
with her atopic diathesis. In addition, serummold speciﬁc IgE levels
using the commercial CAP-FEIA system and serum basal tryptase
(Thermo-Fisher Scientiﬁc Inc, Waltham, Massachusetts) were
measured: tryptase values were in the reference range (5 ng/mL)
and speciﬁc IgE levels were 31.00 kU/L for Penicillium notatum
(positive cutoff limit, 0.35 kU/L), 1.22 kU/L for Aspergillus fumigatus,
47.10 kU/L for Alternaria alternata, and 15.30 kU/L for Penicillium
frequentans. Speciﬁc IgE antibodies to P notatum and Alternaria
tenuis allergens (32100412-PT and 32100400 e NL, Allergopharma,
Reinbek, Germany) were determined by enzyme-linked immuno-
sorbent assay using a commercial kit (Costar 3590; Corning, New
York, New York) according to the manufacturer’s instructions.
Absorbance was measured at 405 nm using a spectrophotometer
and expressed as optical density (OD) units. Samples were assayed
in duplicate, and levels of speciﬁc IgE above 0.145 OD were
considered a positive result.2 Mean levels of speciﬁc IgE to A tenuis
were more than 1.400 OD units, and results were negative (0.145
OD units) in the case of P notatum. Both extracts were analyzed
by sodium dodecyl sulfateepolyacrylamide gel electrophoresis
(SDS-PAGE) as described by Laemmli,3 with protein bands ranging
from11 to 97 kDa. An SDS-PAGE IgE-immunoblot assay revealed IgEextract, with no IgE binding in the Penicillium extract (Fig 1).
Fungal allergen exposure can induce allergic symptoms in the
respiratory tract and skin, whereas generalized reactions are rare.
Few cases of anaphylaxis have been described with the ingestion of
molds and yeasts in patients sensitized to fungi.4
Certain cured meats and cheeses (soft-ripened, washed-rind,
and blue cheeses) require molds as a part of their elaboration.
The application of a mold starter attempts to promote ﬂavor and
prevent pathogenic bacteria from multiplying through proteolytic,
lipolytic, and antioxidant processes. These molds are applied on
the skins and rinds or directly inoculated in the cheese for both
preservation and to add certain tastes and textures. However,
undesirable fungal species may also grow and spoil a food or pro-
duce contamination via mycotoxins. Normally, the products are
inoculated with starters of the Penicillium genus, such as Penicillium
nalgiovense, Penicillium camemberti, Penicillium glaucum, and Peni-
cillium roqueforti, the type of mold used being different depending
on the production regions, but other genera, such as Aspergillus,
Eurotium, Mucor, Rhizopus, Cladosporium, Geotrichum, andFigure 1. IgE binding of proteins in Alternaria tenuis and Penicillium notatum extracts.
Sodium dodecyl sulfateepolyacrylamide gel electrophoresis IgE immunoblotting.
